Compare Summit Therapeutics Inc (SMMT) vs Vanguard Global ex-US Real Estate Index Fd ETF (VNQI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Vanguard Global ex-US Real Estate Index Fd ETF — how do they compare? Summit Therapeutics Inc trades at $17.52 (market cap $13.79B), while Vanguard Global ex-US Real Estate Index Fd ETF trades at $44.53. The key difference: Summit Therapeutics Inc is trading nearer its 52-week high, Vanguard Global ex-US Real Estate Index Fd ETF nearer its low. Which is the better fit depends on your goals.
| SMMT | VNQI | |
|---|---|---|
Market Cap | $13.79B | — |
Sector | Health | — |
52-Week High | $26.38 | $50.76 |
52-Week Low | $12.43 | $43.26 |
Enterprise Value | $13.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.28, down 1.85% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $1.08 billion for 2025, negative ROE of -192.5%, and relies on financing cash flow for liquidity. Recent news highlights positive Phase III trial results for ivonescimab in lung and biliary tract cancers, driving investor optimism ahead of a key FDA decision in November 2026.
The outlook hinges on regulatory approval and commercial success of ivonescimab, with a consensus price target of $25.23 implying 46% upside. Risks include high cash burn, clinical trial uncertainties, and potential dilution from financing activities. Analyst sentiment is bullish (60.9% buy ratings), but the stock remains speculative due to its pre-revenue status and dependence on pipeline milestones.
VNQI (Vanguard Global ex-U.S. Real Estate ETF) trades at $44.95, down 0.71% with a bearish technical signal. The ETF focuses on international real estate across 30+ countries, offering a higher dividend yield than domestic peers but showing lower recent returns. Moving averages indicate selling pressure while oscillators remain neutral. Recent news highlights institutional selling and comparisons with competing real estate ETFs.
The outlook remains cautious due to technical weakness and international real estate market volatility. Investment opportunity lies in global diversification and attractive dividend yield, but risks include currency exposure and underperformance versus U.S. real estate. The bearish technical setup suggests near-term pressure despite neutral fundamental positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Vanguard Global ex-US Real Estate Index Fd ETF
The fund employs an indexing investment approach designed to track the performance of the S&P Global ex-US Property Index, a float-adjusted, market-capitalization-weighted index that measures the equity market performance of international real estate stocks in both developed and emerging markets. The index is composed of stocks of publicly traded equity real estate investment trusts (known as REITs) and certain real estate management and development companies (REMDs).
Read more on VNQI →
